Anti-aging startup Elevian enlists Insilico on AI quest for 'young blood'
Some of the earliest connections Alex Zhavoronkov has built for his AI shop at Insilico Medicine involves marrying anti-aging and AI research, two of the buzziest areas in drug development. He’s now doubling down on it with a new R&D partnership with “young blood” startup Elevian.
The collaboration is aimed at developing oral medications targeting the GDF11, or growth differentiation factor 11, pathway and associated targets — a concept that Elevian has been working on since inception. Elevian is supplying the biological and structural target data that Insilico will use to identify small molecules via its generative adversarial networks (GANs) and reinforcement learning (RL) AI technologies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.